Navigation Links
ev3 Inc. Reports 2008 First Quarter Financial Results and Revised 2008 Guidance
Date:5/2/2008

PLYMOUTH, Minn., May 2 /PRNewswire-FirstCall/ -- ev3 Inc. (Nasdaq: EVVV), a global endovascular device company, today reported financial results for its fiscal first quarter of 2008 and its revised financial guidance for 2008.

As previously reported, ev3's net sales were $101.3 million in the first quarter of 2008 representing a 65% increase over the same quarter of the prior year and a 10% increase over the fourth quarter of 2007. The increase in net sales over the same quarter of the prior year was primarily attributable to the acquisition of FoxHollow. The sequential quarter increase in net sales was driven by growth in the pre-FoxHollow acquisition peripheral vascular business segment and the neurovascular business segment. However, first quarter net sales results were negatively impacted by greater than anticipated sales force integration challenges related to the FoxHollow acquisition and elevated customer inventory levels of SilverHawk products.

Robert Palmisano, president and chief executive officer of ev3 Inc., commented, "While we believe that our fundamental strategies are sound, we have much work ahead of us to improve our execution and efficiency. My top priority will be to continue expanding our position in the peripheral vascular and neurovascular markets globally by offering a full complement of innovative therapies, investing in the development of our next generation of products and pursuing a broad clinical trial agenda to bring new products to market and further validate the scientific foundation of our endovascular procedures. I believe these initiatives will in turn drive growth and shareholder value."

Palmisano commented further, "In resetting our guidance, we took into account the factors that could affect our business in 2008, including the performance of our U.S. atherectomy business, which continues to be adversely affected by elevated customer inventory levels of SilverHawk, the ability of our U.S. peripheral va
'/>"/>

SOURCE ev3 Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. United Therapeutics Reports First Quarter 2008 Financial Results
2. Endocare Reports 2008 First Quarter Financial Results
3. AMICAS Reports Financial Results for the First Quarter Ended March 31, 2008
4. LeMaitre Vascular Reports Q1 2008 Revenue of $11.8 Million, a 20% Increase
5. Anadys Pharmaceuticals Reports First Quarter 2008 Financial Results and Highlights
6. Neurobiological Technologies Reports Receipt of $2.0 Million Royalty Payment for Quarterly Sales of Memantine
7. Alexion Reports First Quarter 2008 Results
8. Masimo Reports First Quarter 2008 Financial Results
9. Cardium Reports on Science Channel Series Featuring InnerCools Endovascular Cooling During Brain Surgery at Stanford University
10. Cynosure Reports 41% Revenue Increase: 10th Consecutive Quarter of Revenue Growth
11. SuperGen Reports 2008 First Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... Aug. 28, 2015 /PRNewswire/ - RepliCel Life Sciences ... medicine company focused on the development of autologous ... quarter ended June 30, 2015, corporate highlights, and ... report are available at www.sedar.com ,  ... "RepliCel expects to launch its RCS-01 ...
(Date:8/28/2015)... ... August 28, 2015 , ... Since the initial launch of FireflySci Inc. (FFS) in ... and excellent customer service. Images such as the Fonz in a lab coat and ... flavor to the humdrum spectroscopy field. , FireflySci is proud to be the ...
(Date:8/27/2015)... ... August 27, 2015 , ... Capital Edge Consulting ... business problems, is pleased to announce their ranking as one of the top 5000 ... the fastest-growing private companies across the nation. , “It is truly an honor to ...
(Date:8/27/2015)... , Aug. 27, 2015 /PRNewswire/ - Portage ... Exchange: PBT.U), and Biohaven Pharmaceutical Holding Company Limited ... a Phase I study of BHV-0223, a glutamate ... (IND) regarding BHV-0223 and recently obtained clearance from ... proceed with human testing. Portage holds 54% equity ...
Breaking Biology Technology:RepliCel Reports Second Quarter 2015 Financial Results 2RepliCel Reports Second Quarter 2015 Financial Results 3RepliCel Reports Second Quarter 2015 Financial Results 4RepliCel Reports Second Quarter 2015 Financial Results 5Cuvette Manufacturer FireflySci Launches Back to School Deals with Complimentary Shipping On All Orders 2Capital Edge Consulting Makes Inc. 5000 List of America’s Fastest-Growing Private Companies 2Capital Edge Consulting Makes Inc. 5000 List of America’s Fastest-Growing Private Companies 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 2Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 4
... You Land a Job , ... San Mateo, CA (PRWEB) July 1, ... hesitate to use the Delete key on your professional resume or bio. ... also be a handicap in the job hunt, says a leading ...
... receive recombinant Bovine Somatotropin (rbST) make more milk, all the ... according to a Cornell University study to be published in ... (June 30, 2008.) , Producing milk uses large quantities ... biotech product used on American farms has been in ...
... Life,Sciences, Inc. (Nasdaq: CALP ), a leading provider ... research, today announced that it has been,added to the ... indexes captures the 4,000,largest U.S. stocks as of the ... in the Russell 3000, which remains in place for,one ...
Cached Biology Technology:Facelift for Resumes Offers Hope for Job Seekers, says Resume Writing Service 2Facelift for Resumes Offers Hope for Job Seekers, says Resume Writing Service 3Carbon hoofprint: Cows supplemented with rbST reduce agriculture's environmental impact 2Caliper Life Sciences Added to Russell 3000(R) Index 2
(Date:8/28/2015)... -- According to a new market research ... (Pen & Paper Based, Hosted, Biometrics), Service, Application (Clinical ... Vertical and Region - Global Forecast to 2020", published ... from USD 2.4 Billion in 2015 to USD 7.5 ... (CAGR) of 25.6% from 2015 to 2020. ...
(Date:8/26/2015)... The report "Multi-Factor Authentication (MFA) Market ... (Travel & Immigration, Government, Banking, Defense, Commercial Security, Consumer ... published by MarketsandMarkets, Multi-Factor Authentication Market is expected to ... CAGR of 17.7% between 2015 and 2020. ... spread through 169 P ages and ...
(Date:8/25/2015)... BELLEVUE, Wash. , Aug. 25, 2015 /PRNewswire/ ... announced today it will unveil its "Guardian S" snake ... the National Tactical Officers Association Conference on August 30 ... S is the first-ever commercially available energetically autonomous snake ... and in-field trials and is protected by more than ...
Breaking Biology News(10 mins):Cognitive Assessment and Training Market Worth 7.5 Billion USD by 2020 2Cognitive Assessment and Training Market Worth 7.5 Billion USD by 2020 3Cognitive Assessment and Training Market Worth 7.5 Billion USD by 2020 4Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 2Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 3Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 4Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 5Sarcos to Debut First-of-its-Kind Snake Robot 2Sarcos to Debut First-of-its-Kind Snake Robot 3
... Biologists have tracked down genes that control the handedness of ... the genes used by humans to set up the left ... online in advance of publication in Nature by ... have been responsible for establishing the left-right asymmetry of animals ...
... a licensing deal to enable bio-based production of ... drugs and solvents and as a food additive. ... advanced starch and starch-derivatives businesses, was intrigued by ... produce bio-based succinic acid from renewable resources via ...
... 2008 The Translational Genomics Research Institute (TGen), Scottsdale ... that could help cancer patients by stimulating the immune ... being conducted at TGen Clinical Research Services at Scottsdale ... Healthcare Corp., and at Mayo Clinic in Arizona. ...
Cached Biology News:Snails and humans use same genes to tell right from left 2Snails and humans use same genes to tell right from left 3Snails and humans use same genes to tell right from left 4'Green' chemicals closer to market 2TGen, Scottsdale Healthcare, Mayo Clinic study new drug to stimulate immune system of cancer victims 2
This kit is designed to select cells labeled with biotinylated antibodies. Kit includes reagents for labeling 3 x 10 9 cells and EasySep magnet....
Designed for use with the Agencourt CleanSEQ and Agencourt AMPure 384-well SPRI reagent kits. For use with 384-well thermal cycling plates....
SDS-OutT Precipitation Reagent...
Physical Form: saline suspension with ethanol Particle Dim: mean particle size 50 μm Matrix: HyperD F. Useful for the removal of detergents from protein samples....
Biology Products: